Evidence map›Paper›PMID 32291277›Full record

Trial reportDiabetes care2020

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.

Mark L Hartman, Arun J Sanyal, Rohit Loomba, Jonathan M Wilson, Amir Nikooienejad, Ross Bray, Chrisanthi A Karanikas, Kevin L Duffin, Deborah A Robins, Axel Haupt

Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 186 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
186citing papers in PubMed, 9 pooled it
28.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

186 citing papers in PubMed, 9 syntheses or guidelines pooled it, 328 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. GLP-1a: Going beyond Traditional Use.International journal of molecular sciences · 2022
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Review
  18. Review
  19. Review
  20. Review

126 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mark L HartmanEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN hartman_mark_l@lilly.com.ORCID 0000-0003-2396-7356
Arun J SanyalDivision of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA.
Rohit LoombaNAFLD Research Center, Department of Medicine, University of California, San Diego, La Jolla, CA.
Jonathan M WilsonEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.
Amir NikooienejadEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.
Ross BrayEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.
Chrisanthi A KaranikasEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.
Kevin L DuffinEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.
Deborah A RobinsEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.ORCID 0000-0001-9694-7319
Axel HauptEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN.
Eli Lilly (United States) · USUniversity of California San Diego · USVirginia Commonwealth University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo determine the effect of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of nonalcoholic steatohepatitis (NASH) and fibrosis in patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND

methodsPatients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks. Changes from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST), keratin-18 (K-18), procollagen III (Pro-C3), and adiponectin were analyzed in a modified intention-to-treat population.

resultsSignificant (

conclusionsIn post hoc analyses, higher tirzepatide doses significantly decreased NASH-related biomarkers and increased adiponectin in patients with T2DM.

Indexed as

AdultAlanine TransaminaseAspartate AminotransferasesBiomarkersDiabetes Mellitus, Type 2FemaleGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHumansImmunoglobulin Fc FragmentsLiver CirrhosisMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseReceptors, Gastrointestinal HormoneAlanine TransaminaseAspartate AminotransferasesBiomarkersdulaglutideGastric Inhibitory Polypeptidegastric inhibitory polypeptide receptorGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesImmunoglobulin Fc FragmentsReceptors, Gastrointestinal HormoneRecombinant Fusion ProteinsTirzepatide

Identifiers

PMID32291277
PMCPMC7245348
OpenAlexW3015345942

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.